HCV Next Current Issue
The following articles appeared in the print edition of HCV Next.
Table of Contents
- A Matter of Compensation: HCV and Cirrhosis
-
- A Conversation with Michael S. Saag, MD
- Putting Together the Pieces: Cirrhosis, Osteoporosis and Aging
- Breaking Down the Connection Between HCV and Bone Disorders
- Beclabuvir with PEG-IFN a-2a/Ribavirin Safely Treated HCV
- Cognitive Impairment Associated with HCV in Children
- HBV, HCV in Mothers Led to Increased Risk for Neurological Outcomes in Infants
- HCV with 1p36.3 Mutation may Contribute to Cancer Risk
- Opioid Use Lowered HCV Incidence in Young Adult Injection Drug Users
-
- Rheumatic Hand Manifestations Observed in Chronic HCV
- Switch to Sirolimus Improved Outcomes in Liver Transplantation
- Telaprevir, Boceprevir not Toxic in Real-World Study
- Treating the Elderly with HCV: Unique Complications, Considerations Paul Martin, MD, AGAF
- Added Benefit of HCV Drug Unproven Due to Insufficient Data
- Clinical Setbacks Integral to Long-Term Success in HCV Treatment
- FDA Approves Test Used to Screen Blood for HIV and HBV, HCV
- HCV Trial of ‘One-Shot’ Drug Continues
-
- Prime Therapeutics to Supply Competing Therapies for HCV